timothy sykes logo

Stock News

TG Therapeutics: Surge or Stall?

Matt MonacoAvatar
Written by Matt Monaco Reviewed by Jack Kellogg Fact-checked by Tim Sykes
TG Therapeutics: Surge or Stall? Thumbnail

TG Therapeutics Inc.’s stock price has surged after positive news regarding its new FDA approval for a groundbreaking multiple sclerosis drug, with the stock trading up by 14.0 percent on Monday.

Key Developments and Market Reactions

  • TG Therapeutics acquired rights to use MaxCyte’s cutting-edge technology for developing their CAR T cell therapy, aimed at treating autoimmune diseases.
  • Plans are in motion for a Phase 1 trial of Precision’s CD19 CAR T cell therapy, underscoring their focus on addressing multiple sclerosis.
  • The company has scheduled a forthcoming conference call in early March to discuss the financial results and strategic outlook for the 2025 fiscal year.

Candlestick Chart

Live Update At 17:20:47 EST: On Monday, March 03, 2025 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 14.0%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Snapshot: TG Therapeutics Inc.’s Recent Performance

When traders are faced with a volatile market, it can be easy to feel overwhelmed by the fear of missing out. Many newcomers make impulsive decisions, driven by emotions rather than strategy. However, seasoned traders understand the importance of patience and timing. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” By keeping this in mind, traders can avoid hasty moves and focus on making well-informed choices, knowing opportunities will always emerge around the corner.

TG Therapeutics Inc. has been making waves in the biotechnology world, not just for its stock market performance but also for strategic moves in its treatments and technologies. For the past few weeks, their stock has seen notable fluctuations, closing at $34.42 on Mar 03, 2025. The highs and lows tell a tale of potential coupled with market hesitation. Opening at $30.33, the stock hit a high of $36.4 but later settled, showing both confidence and caution among investors.

The recent financials paint a mixed picture. With an unexpected but modest increase in revenue to $233.66M, their operating income stayed in positive territory, albeit with a thin margin. Although operating costs remain on the higher side, TG Therapeutics has managed to keep a strong gross margin of 88.3%, demonstrating operational efficiency.

Their earnings in the past quarter revealed a resilient performance with $8.39M in total revenue, a 3% improvement from the previous period. Their net income of $3.88M symbolizes a step forward, but keeping profits steady in the coming quarters remains vital. Analysts eye the company’s price-to-sales ratio at 17.69 as a potential area for growth.

While evaluating financial strength, TG Therapeutics shows potential with a current ratio of 4.6, signaling robust liquidity. A quick ratio of 3.7 further showcases their ability to address immediate obligations. However, their total debt-to-equity of 1.32 could indicate room for strategic financial restructuring to optimize long-term growth.

More Breaking News

With revenue per share at $1.5 and ongoing research investments, they seem committed to future growth. The consistent R&D investments tell of a story more profound than just numbers—a quest to innovate in healthcare.

Blending Science and Market Strategies

Strategically, TG Therapeutics’ recent acquisition of technology for CAR T cell therapy signifies forward-thinking momentum. This step hints at a promising direction not just for tackling autoimmune diseases but also consolidating expertise in cell and gene therapies.

This endeavor feeds into their broader strategy of leveraging biotechnology for patient-centric solutions. The anticipation around the Phase 1 trial for their multiple sclerosis solution adds credence to their emphasis on cutting-edge solutions to age-old ailments. For keen observers, the news suggests a robust pipeline that could buoy stock prices with tangible clinical successes.

Market Sentiment and Stock Performance Outlook

The upcoming call on Mar 03, 2025, is a flashlight on the company’s fiscal future plans. Investors and analysts alike will undoubtedly scrutinize it for cues on strategic focus, revenue projections, and product investments. Despite its challenges, TG Therapeutics holds promise embedded in its strategic ventures and collaborative initiatives.

Their progress, cast against a backdrop of sector-wide innovation endeavors, offers a canvas of both hopeful and cautious investors. Near-term stock movements will likely reflect the company’s calls and real-world performance in clinical settings.

Stock sentiment remains a unique blend of optimism and skepticism, a testament to biotechnology’s inherent complexities. While stakeholder enthusiasm peaks with new announcements, market investors will likely maintain a watchful eye until the costs and benefits of these endeavors mature fully.

Conclusion: Skies Clear or Cloud Ahead?

To the ardent trader or investor, TG Therapeutics presents a puzzle. Does the recent uptick in strategic partnerships and trial plans promise more than uncertainty’s cloud? As the narrative unfolds, the market’s verdict on TG Therapeutics will likely be inked not just in stock prices but in clinical and therapeutic milestones.

As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This sentiment is keenly felt as riding this technological wave demands both patience and persistence. Whether a rising star or merely a momentary ripple reveals itself at the intersection of time and transparent market maneuvers. The question is, where does TG Therapeutics anchor its journey in this biotechnology odyssey?

This content is produced using automated systems designed to deliver timely stock news. All material is reviewed by our editorial team and is provided solely for informational and entertainment purposes. It does not constitute professional investment advice. For additional details, please refer to our [Terms of Service]

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”